Neoplasms — Expanded Access Programs
Overview
Right2Hope maintains a directory of 34 expanded access programs, clinical trials, and compassionate use pathways listed for Neoplasms. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with neoplasms programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 11 programs are currently active or recruiting, with the remaining 23 in other lifecycle stages. Sponsors actively running programs in this area include GlaxoSmithKline, Shanghai EpimAb Biotherapeutics Co., Ltd., Adaptimmune, Advanced Accelerator Applications, Alliance for Clinical Trials in Oncology, and others.
By recruiting status
Snapshot of where every Neoplasms program currently sits in its lifecycle.
- Active / Recruiting11
- Inactive23
Top sponsors
Organisations running the most Neoplasms programs in the directory.
- GlaxoSmithKline4 programs
- Shanghai EpimAb Biotherapeutics Co., Ltd.2 programs
- Adaptimmune1 program
- Advanced Accelerator Applications1 program
- Alliance for Clinical Trials in Oncology1 program
- BTG International Inc.1 program
- Celgene1 program
- Corcept Therapeutics1 program
- Eisai Inc.1 program
- Eli Lilly and Company1 program
Neoplasms programs (34)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on E7386 Combined with Other Cancer Drugs for Patients with Solid Tumors — Eisai Inc.
- Study on Encorafenib and Cetuximab With or Without Chemotherapy for Untreated Metastatic Colorectal Cancer — Pfizer
- Study Comparing Dostarlimab with Chemotherapy to Placebo with Chemotherapy in Advanced Endometrial Cancer — Tesaro, Inc.
- Study on the Safety and Effects of JNJ-63723283, an Anti-PD-1 Antibody, in People with Advanced Cancers — Janssen Research & Development, LLC
- Study on the Safety and Initial Effectiveness of GSK5460025 Alone or with Other Cancer Treatments in Patients with Solid Tumors — GlaxoSmithKline
- Extended Access to Momelotinib for Adults with Myelofibrosis — GlaxoSmithKline
- Study on Genetically Engineered T Cells for Treating Solid Tumors with NY-ESO-1 and/or LAGE-1a Proteins — Adaptimmune
- Study on Pocenbrodib Alone and in Combination with Other Treatments for Advanced Prostate Cancer — Pathos AI, Inc.
- Study on the Safety and Effectiveness of Lete-Cel in Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma — USWM CT, LLC
- Study on the Safety and Effectiveness of Lete-Cel for Treating Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma — USWM, LLC (dba US WorldMeds)
- Study on Nenocorilant and Nivolumab Combination for Advanced Solid Tumors — Corcept Therapeutics
- Study on [177Lu]-NeoB for Patients with Advanced Solid Tumors Showing [68Ga]-NeoB Uptake — Advanced Accelerator Applications
- Study on the Impact of 18F-Fluciclovine PET/CT on Predicting Outcomes of 177Lu-PSMA-617 Therapy in Prostate Cancer Patients — VA Greater Los Angeles Healthcare System
- Study on EMB-01 Dose Escalation and Expansion for Adults with Advanced or Metastatic Solid Tumors — Shanghai EpimAb Biotherapeutics Co., Ltd.
- Study on Multiple Drug Trials for Children and Young Adults with Cancer — Eli Lilly and Company
- Continued Treatment Study for Patients with ALK-Positive or RET-Positive Cancer Using Alectinib or Crizotinib — Hoffmann-La Roche
- Study on STAR0602 for Treating Advanced Solid Tumors — Marengo Therapeutics, Inc.
- Study on AdAPT-001 for Patients with Sarcoma and Hard-to-Treat Solid Tumors — EpicentRx, Inc.
- Study on LY2880070 for Patients with Advanced or Metastatic Cancer — Esperas Pharma Inc.
- Study on Iobenguane (131-I) and Vorinostat for Treating Recurrent or Progressive High-Risk Neuroblastoma — Jubilant DraxImage Inc.
- Study on the Safety and Effects of GSK4524101 Alone or with Niraparib in Patients with Solid Tumors — GlaxoSmithKline
- Study on EMB-01 for Patients with Advanced Gastrointestinal Cancers — Shanghai EpimAb Biotherapeutics Co., Ltd.
- Expanded Access Program for Taletrectinib in Patients with Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer — Nuvation Bio Inc.
- Study on HSV G207 Virus Therapy with Radiation for Children with Recurrent High-Grade Brain Tumors — Pediatric Brain Tumor Consortium
- Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells — Celgene
- Phase 2 Study of NKT2152 with Palbociclib and Sasanlimab for Advanced Clear Cell Kidney Cancer — NiKang Therapeutics, Inc.
- Study Comparing New Treatments to Standard Care in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) — GlaxoSmithKline
- Study on Nilotinib and Paclitaxel for Treating Rare Cancers — National Cancer Institute (NCI)
- Study on the Safety and Effectiveness of Bevacizumab with NaviFUS System for Treating Recurrent Glioblastoma Multiforme — NaviFUS Corporation
- Study of Abemaciclib and Elacestrant for Patients with Brain Metastasis from ER+/HER-2- Breast Cancer — Stemline Therapeutics, Inc.
- Study on CD30 CAR Therapy for Relapsed or Hard-to-Treat CD30+ Hodgkin and Non-Hodgkin Lymphoma — UNC Lineberger Comprehensive Cancer Center
- Study on the Effect of Denosumab in Preventing Breast Cancer in Women with a BRCA1 Gene Mutation — Alliance for Clinical Trials in Oncology
- Treatment Plan for Voraxaze in Patients with High Methotrexate Levels — BTG International Inc.
- Vorasidenib Access Program for Patients with IDH1 or IDH2 Mutated Glioma — Servier
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Neoplasms to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.